Abstract
Obesity and pulmonary hypertension (PH) frequently coexist, but obesity is not a distinct PH group. This narrative review of the literature published through 27 September 2026 appraises the evidence by PH group. Obesity is most clearly linked to PH through intermediate conditions, particularly heart failure with preserved ejection fraction, obstructive sleep apnea, and obesity hypoventilation syndrome, and it can complicate hemodynamic classification because elevated intrathoracic pressure may raise the measured pulmonary arterial wedge pressure. Experimental studies suggest direct pulmonary vascular effects through adipokine imbalance, inflammation, altered estrogen metabolism, oxidative stress, and insulin resistance; however, an independent causal role of obesity in human pulmonary arterial hypertension has not been established. Small, mostly observational studies report lower estimated pulmonary pressures after bariatric surgery, but a benefit of intentional weight loss on invasive hemodynamics or clinical PH outcomes is unproven. Incretin-based therapies produce substantial weight loss and improve symptoms in obesity-related heart failure with preserved ejection fraction; acute human hemodynamic data are emerging, but long-term efficacy in PH has not been tested. Higher body mass index has been associated with lower observed mortality in several PH cohorts, possibly reflecting confounding and reverse causation. We distinguish established findings from hypotheses and highlight research priorities.

This publication has 95 references indexed in Scilit: